Sacrosidase

Identification

Summary

Sacrosidase is an enzyme replacement therapy used for the treatment of congenital sucrase-isomaltase deficiency (CSID).

Brand Names
Sucraid
Generic Name
Sacrosidase
DrugBank Accession Number
DB06760
Background

Sacrosidase is a liquid enzyme preparation from S.cerevisiae used for the treatment of congenital sucrose-isomaltase deficiency (CSID). People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issues metabolizing dietary disaccharide sucrose causing chronic or intermittent watery diarrhea in infants and children. Treatment options for these patients are limited and usually consists of a lifelong sucrose-free diet; therefore, sacrosidase offers a potential alternative for symptom relief.

Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Other protein based therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Sacrosidase

Pharmacology

Indication

For the treatment of congenital sucrose-isomaltase deficiency (CSID).

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Sacrosidase is a [beta]-fructofuranoside fructohydrolase that hydrolyzes sucrose. Unlike human intestinal sucrase-isomaltase, it has no activity with oligosaccharides containing 1,6 glucosyl bonds.

Absorption

It has been suggested that sucrose is better absorbed (and sacrosidase activity preserved) when patients were given milk before sacrosidase rather than consuming the enzyme product alone. Therefore, it has been recommended to take half dose of sacrosidase just after a protein-containing meal, and the other half of the dose approximately half-way through the meal.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
International/Other Brands
Sucraid
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
SucraidSolution, concentrate8500 [iU]/1OralQOL Medical, LLC2006-06-162006-06-16US flag
SucraidSolution8500 [iU]/1mLOralQOL Medical, LLC1998-04-09Not applicableUS flag

Categories

ATC Codes
A16AB06 — Sacrosidase
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
8A7F670F2Y
CAS number
85897-35-4

References

General References
  1. Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J: Sacrosidase therapy for congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 1999 Feb;28(2):137-42. [Article]
KEGG Drug
D05782
PubChem Substance
347910368
RxNav
214817
ChEMBL
CHEMBL1201487
Drugs.com
Drugs.com Drug Page
Wikipedia
Sacrosidase

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4WithdrawnTreatmentCongenital Sucrase-isomaltase Deficiency (CSID)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionOral8500 [iU]/1mL
Solution, concentrateOral8500 [iU]/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US9469847No2016-10-182034-02-07US flag
US9849161No2017-12-262034-02-07US flag
US9255261No2016-02-092034-02-07US flag

Properties

State
Solid
Experimental Properties
Not Available

Drug created on September 14, 2010 16:21 / Updated on February 21, 2021 18:52